Should empiric therapies be used for male factor infertility?

Fertile Battle

Editorial Office, American Society for Reproductive Medicine

Published Jun 17, 2020

Volume 113, Issue 6, Pages 1121–1130

Authors:

Kai J. Buhling, M.D., Peter Chan, M.D., Martin Kathrins, M.D., Marian Showell, M.P.H., M.L.I.S., Sarah C. Vij, M.D., Mark Sigman, M.D.

Abstract:

PRO: Empiric therapies should be used for male factor infertility

CON: Empiric therapies should not be used for male factor infertility

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.

Should empiric therapies be used for male factor infertility?

Share

Volume 113, Issue 6, Pages 1121–1130

Authors:

Abstract:

Fertility and Sterility

You may also be interested in...

Should women undergoing in vitro fertilization treatment or who are in the first trimester of pregnancy be vaccinated immediately against COVID-19

Reproductive Endocrinology and Infertility fellowship programs: Does one size fit all?

Should couples with unexplained infertility have three to six cycles of intrauterine insemination with ovarian stimulation or in vitro fertilization as first-line treatment?

Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons